Alex Friedlaender
University of Geneva
CancerInternal medicineOncologyIntensive care medicineLung cancerChemotherapyPerformance statusImmunotherapyDiseasePembrolizumabPD-L1AdenocarcinomaKRASTargeted therapyNon small cellImmune checkpoint inhibitorsCancer researchBreast cancerMedicineCohort
76Publications
16H-index
485Citations
Publications 82
Newest
#1Daniele Frisone (Geneva College)H-Index: 1
#2Alex Friedlaender (Geneva College)H-Index: 16
Last. Alfredo Addeo (Geneva College)H-Index: 22
view all 3 authors...
PURPOSE OF REVIEW There has been a huge development in the assessment of malignancies through liquid biopsies last years, especially for NSCLC, where its use has become part of clinical practice in some settings. We aim to summarize current evidence about minimal residual disease and its use in lung cancer. RECENT FINDINGS Recent studies using ctDNA in NSCLC but also in other types of cancer found strong correlations between the presence of ctDNA and the risk of disease progression or death afte...
Source
#1Alfredo AddeoH-Index: 22
#2Alex FriedlaenderH-Index: 16
Last. Christian Rolfo (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 46
view all 8 authors...
Purpose of review null Cancer vaccines are one of the most extensively studied immunotherapy type in solid tumors. Despite favorable presuppositions, so far, the use of cancer vaccines has been associated with disappointing results. However, a new generation of vaccines has been developed, promising to revolutionize the immunotherapy field. null Recent findings null In this review, we aim to highlight the advances in cancer vaccines and the remaining hurdles to overcome. Cancer vaccination has e...
Source
#1Florian Laubscher (Geneva College)H-Index: 7
#2Samuel Cordey (Geneva College)H-Index: 20
Last. Stéphanie Baggio (University of Geneva)H-Index: 23
view all 14 authors...
Background: Oncological patients have a higher risk of prolonged SARS-CoV-2 shedding, which, in turn, can lead to evolutionary mutations and emergence of novel viral variants. The aim of this study was to analyze biological samples of a cohort of oncological patients by deep sequencing to detect any significant viral mutations. Methods: High-throughput sequencing was performed on selected samples from a SARS-CoV-2-positive oncological patient cohort. Analysis of variants and minority variants wa...
Source
#1Alex Friedlaender (Geneva College)H-Index: 16
#2Vivek Subbiah (University of Texas MD Anderson Cancer Center)H-Index: 55
Last. Alfredo Addeo (Geneva College)H-Index: 22
view all 7 authors...
Source
#1Alex Friedlaender (Geneva College)H-Index: 16
#2Vivek Subbiah (University of Texas MD Anderson Cancer Center)H-Index: 55
Last. Alfredo Addeo (Geneva College)H-Index: 22
view all 7 authors...
Protein tyrosine kinases of the human epidermal growth factor receptor family, including EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung, breast and gastroesophageal cancers, and are of relevance for the treatment of various other malignancies (particularly colorectal cancer). Classic activating EGFR exon 19 deletions and exon 21 mutations, and HER2 amplification and/or overexpression, are predictive of response to matched molecularly targeted therapies, trans...
Source
#2Ornella CantaleH-Index: 4
Last. Addeo Alfredo (Geneva College)H-Index: 1
view all 6 authors...
The impact of systemic anticancer treatments on SARS-CoV-2-related mortality is still debatable.By a retrospective analysis of patients with non-small-cell lung cancer (NSCLC) treated with first-li...
Source
Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of therapeutic options for many cancers. These treatments have demonstrated improved efficacy and often a more favourable toxicity profile compared to standard cytotoxic chemotherapy. There are considerable differences among responders, with some patients experiencing durable long-term disease control and even remission. Given this variability, determining a proper biomarker to select patients for ICI therapy has become increa...
Source
#2Alessio CortelliniH-Index: 20
Last. Pamela PizzutiloH-Index: 9
view all 46 authors...
Source
#1Alfredo Addeo (University of Geneva)H-Index: 22
Last. Alex Friedlaender (University of Geneva)H-Index: 16
view all 3 authors...
Lung cancer represents the most common form of cancer, accounting for 1.8 million deaths globally in 2020. Over the last decade the treatment for advanced and metastatic non-small cell lung cancer have dramatically improved largely thanks to the emergence of two therapeutic breakthroughs: the discovery of immune checkpoint inhibitors and targeting of oncogenic driver alterations. While these therapies hold great promise, they face the same limitation as other inhibitors: the emergence of resista...
Source
#1Alfredo AddeoH-Index: 22
Last. Alex FriedlaenderH-Index: 16
view all 3 authors...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.